Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EM1H | ISIN: US03770N1019 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:59
43,410 US-Dollar
-0,91 % -0,400
1-Jahres-Chart
APOGEE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APOGEE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APOGEE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.06.Apogee Therapeutics stock maintains buy rating at Stifel ahead of data2
11.06.Apogee Therapeutics stock maintains buy rating ahead of key trial data1
APOGEE THERAPEUTICS Aktie jetzt für 0€ handeln
11.06.Apogee Therapeutics-Aktie behält Kaufempfehlung vor wichtigen Studiendaten2
27.05.Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock12
12.05.BTIG maintains Apogee Therapeutics stock Buy rating, $100 target3
12.05.Why Is Apogee Therapeutics Stock Trading Higher On Monday?4
12.05.Apogee Therapeutics reports positive results from asthma treatment trial5
12.05.Apogee Therapeutics, Inc. - 10-Q, Quarterly Report2
12.05.Apogee Therapeutics, Inc. - 8-K, Current Report-
12.05.Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results348Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in...
► Artikel lesen
12.05.Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma317Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%...
► Artikel lesen
07.05.Stifel maintains $95 target on Apogee Therapeutics stock3
11.03.Apogee Therapeutics, Inc. - 8-K, Current Report-
10.03.TD Cowen reiterates buy on Apogee Therapeutics stock2
03.03.Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial1
03.03.Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy4
03.03.Apogee Therapeutics reports FY results3
03.03.Apogee Therapeutics, Inc. - 8-K, Current Report-
03.03.Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results362Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)...
► Artikel lesen
03.03.Apogee Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1